HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44
JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate
Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating
TD Cowen Initiates Coverage On Odyssey Therapeutics with Buy Rating
Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30
JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics Begins IPO Rollout
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
